We co-cultured MV4-11 cells (a FLT3-ITD mutation AML cell line) with BMSCs and tested the sensitivity of sorafenib, a TKI proved by Food and Drug Administration for hepatocellular carcinoma and renal cell carcinoma. This evidence concerns the gene FLT3 and hereditary clear cell renal cell carcinoma.